Joanna Opalińska

GlaxoSmithKline (United States) — United States

Medicine · Health Sciences

12h-index800citations52works17.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(48), Protein Degradation and Inhibitors(22), Peptidase Inhibition and Analysis(16), Monoclonal and Polyclonal Antibodies Research(11), Retinoids in leukemia and cellular processes(5)

Publications52 total

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study
Blood·2025Open Access
Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
MM-1045: Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin (Belamaf) Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
POSTER: MM-1045 Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin (Belamaf) Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MM-1486 Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
MM-1486: Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
The Lancet Oncology·2025· 7 cited
Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).
Journal of Clinical Oncology·2025· 1 cited
Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial.
Journal of Clinical Oncology·2025
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Blood Cancer Journal·2024· 3 citedOpen Access
P-413 Characterization and Management of Ocular Events in Patients Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in the DREAMM-8 Study
Clinical Lymphoma Myeloma & Leukemia·2024· 8 cited
P-396 Characterization and Management of Ocular Events in Patients (Pts) Treated With Belantamab Mafodotin (Belamaf) Plus Bortezomib and Dexamethasone (BVd) in the DREAMM-7 Study
Clinical Lymphoma Myeloma & Leukemia·2024· 6 cited
OA-62 Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2024· 9 cited
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
New England Journal of Medicine·2024· 122 cited
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
New England Journal of Medicine·2024· 127 cited
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Cancer·2024· 8 citedOpen Access
Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3
Blood·2023· 4 cited
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
The Lancet Haematology·2023· 113 cited
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma
Journal of the Advanced Practitioner in Oncology·2023· 3 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Suzanne Trudel(20), Meletios Α. Dimopoulos(17), Ira Gupta(16), Kihyun Kım(12), Brandon E. Kremer(12), Sosana Delimpasi(12), Sagar Lonial(11), Ashraf Badros(11), Katja Weisel(11), Paweł Robak(11), Astrid McKeown(11), Hang Quach(11), Neal Sule(11), Rakesh Popat(11), Michèle Cavo(10), Vladimir Vorobyev(10), Kazuhito Suzuki(10), Roxanne C. Jewell(10), Eric Lewis(9), María‐Victoria Mateos(9)